within Pharmacolibrary.Drugs.P_AntiparasiticProductsInsecticidesAndRepellents.P01A_AgentsAgainstAmoebiasisAndOtherProtozoalDiseases.P01AX06_Atovaquone;

model Atovaquone
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_2C_enteral(
    weight = 70,
    F = 0.23,
    Cl = 2.9166666666666666e-06,
    adminDuration = 600,
    adminMass = 750 / 1000000,
    adminCount = 1,
    Vd = 0.0088,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    ka = 0.0005,
    Tlag = 600,
    Vdp = 0.0053,
    k12 = 1.0888888888888889e-06,
    k21 = 1.0888888888888889e-06);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Atovaquone</td></tr><tr><td>ATC code:</td><td>P01AX06</td></tr><td>route:</td><td>oral</td></tr>
    <tr><td>compartments:</td><td>2</td></tr>
    <tr><td>dosage:</td><td>750</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>8.8</td><td>L</td></tr>
    <tr><td>clearance:</td><td>0.15</td><td>L/h/kg</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Atovaquone is a hydroxynaphthoquinone antiprotozoal medication primarily used for the treatment and prevention of Pneumocystis jirovecii pneumonia (PCP), toxoplasmosis, and in combination with proguanil for malaria treatment and prophylaxis. It is approved for use in many countries.</p><h4>Pharmacokinetics</h4><p>Population pharmacokinetic model of atovaquone in healthy adult volunteers after oral administration.</p><h4>References</h4><ol><li><p>Hussein, Z, et al., &amp; Canfield, CJ (1997). Population pharmacokinetics of atovaquone in patients with acute malaria caused by Plasmodium falciparum. <i>Clinical pharmacology and therapeutics</i> 61(5) 518–530. DOI:<a href=\"https://doi.org/10.1016/S0009-9236(97)90132-6\">10.1016/S0009-9236(97)90132-6</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/9164414/\">https://pubmed.ncbi.nlm.nih.gov/9164414</a></p></li><li><p>Hussein, Z, et al., &amp; Canfield, CJ (1996). Population pharmacokinetics of proguanil in patients with acute P. falciparum malaria after combined therapy with atovaquone. <i>British journal of clinical pharmacology</i> 42(5) 589–597. DOI:<a href=\"https://doi.org/10.1111/j.1365-2125.1996.tb00114.x\">10.1111/j.1365-2125.1996.tb00114.x</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/8951190/\">https://pubmed.ncbi.nlm.nih.gov/8951190</a></p></li><li><p>McGready, R, et al., &amp; Nosten, F (2003). The pharmacokinetics of atovaquone and proguanil in pregnant women with acute falciparum malaria. <i>European journal of clinical pharmacology</i> 59(7) 545–552. DOI:<a href=\"https://doi.org/10.1007/s00228-003-0652-9\">10.1007/s00228-003-0652-9</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/12955371/\">https://pubmed.ncbi.nlm.nih.gov/12955371</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.P.P01AX06 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Atovaquone;
